MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Interpace Biosciences Net Income 2011-2026 | IDXG
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Interpace Biosciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.7 M | 1.95 M | -22 M | -14.9 M | -26.5 M | -26.7 M | -12.2 M | -12.2 M | -8.33 M | -11.4 M | -16.1 M | -4.56 M | -25.5 M | -11.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.7 M | -26.7 M | -13.1 M |
Quarterly Net Income Interpace Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 911 K | -640 K | 1.65 M | - | 1.68 M | 2.44 M | 708 K | - | -614 K | 175 K | 351 K | - | -14.2 M | -3.94 M | -2.25 M | - | -3.56 M | -3.45 M | -4.21 M | -8.14 M | -6.23 M | -5.58 M | -6.49 M | -10.7 M | -7.45 M | -5.3 M | -3.33 M | -4.3 M | -3.13 M | -2 M | -3.28 M | - | -3.4 M | -6.39 M | 2.33 M | - | -8 M | -2.84 M | -5.3 M | - | -5.4 M | -7.49 M | -4.61 M | - | -4.45 M | -2.66 M | -1.61 M | - | -2.14 M | -883 K | 2.13 M | - | -1.02 M | -439 K | -272 K | - | -202 K | -895 K | -550 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.44 M | -14.2 M | -3.02 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46.9 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Anixa Biosciences
ANIX
|
-10.9 M | $ 3.01 | -2.9 % | $ 97.7 K |  USA |
|
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
-27.2 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Brainsway Ltd.
BWAY
|
-6.46 M | $ 23.56 | -2.04 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 33.99 | 0.65 % | $ 366 M |  China |
 |
Accelerate Diagnostics
AXDX
|
-14.6 M | - | -61.36 % | $ 2.46 M | USA |
 |
BioNano Genomics
BNGO
|
-112 M | $ 1.38 | -6.12 % | $ 1.75 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.1 M | - | - | $ 9.42 M | Israel |
 |
Oxford Immunotec Global PLC
OXFD
|
-1.81 M | - | - | $ 562 M |  Britain |
 |
Castle Biosciences
CSTL
|
18.2 M | $ 39.01 | -0.38 % | $ 1.08 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
-35.3 M | - | - | $ 79.8 M | USA |
 |
Danaher Corporation
DHR
|
3.9 B | $ 218.94 | -0.24 % | $ 160 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-865 M | $ 102.48 | 0.18 % | $ 19 B | USA |
 |
DermTech
DMTK
|
-101 M | - | -11.32 % | $ 2.94 M | USA |
 |
Global Cord Blood Corporation
CO
|
501 M | - | - | $ 399 M | China |
 |
Fulgent Genetics
FLGT
|
-42.7 M | $ 26.01 | -0.88 % | $ 786 M | USA |
 |
Fluidigm Corporation
FLDM
|
-53 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-7.13 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-503 M | - | 0.12 % | $ 80.1 M | China |
 |
Guardant Health
GH
|
-436 M | $ 111.89 | 1.28 % | $ 13.7 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
197 M | - | - | $ 10.7 B | USA |
 |
DexCom
DXCM
|
542 M | $ 73.26 | -1.0 % | $ 28.3 B | USA |
 |
CareDx, Inc
CDNA
|
-190 M | $ 20.4 | -1.92 % | $ 1.1 B | USA |
 |
Celcuity
CELC
|
-112 M | $ 109.94 | -1.94 % | $ 4.34 B | USA |
 |
DarioHealth Corp.
DRIO
|
-59.4 M | $ 10.95 | 6.31 % | $ 311 M | Israel |
 |
Enzo Biochem
ENZ
|
-26.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Lantheus Holdings
LNTH
|
312 M | $ 65.82 | -1.3 % | $ 4.55 B | USA |
 |
Heska Corporation
HSKA
|
-19.9 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-21.6 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-1.22 B | $ 145.95 | -2.5 % | $ 23.2 B | USA |
 |
QIAGEN N.V.
QGEN
|
83.6 M | - | - | $ 10.6 B |  Niderland |
 |
IQVIA Holdings
IQV
|
1.37 B | $ 230.03 | -2.31 % | $ 41.7 B | USA |
 |
NeoGenomics
NEO
|
-78.7 M | $ 11.85 | -4.44 % | $ 1.5 B | USA |
 |
Charles River Laboratories International
CRL
|
22.2 M | $ 210.0 | -0.83 % | $ 10.8 B | USA |
 |
Medpace Holdings
MEDP
|
404 M | $ 583.39 | -1.63 % | $ 18.1 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
871 M | $ 184.82 | 1.37 % | $ 20.5 B | USA |
|
Biodesix
BDSX
|
-42.9 M | $ 8.94 | -7.45 % | $ 1.16 B | USA |
 |
Personalis
PSNL
|
-81.3 M | $ 9.4 | -5.72 % | $ 557 M | USA |
 |
Motus GI Holdings
MOTS
|
-12.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Precipio
PRPO
|
-5.85 M | $ 24.39 | 0.54 % | $ 31.7 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
746 M | $ 269.39 | -0.16 % | $ 22.6 B | USA |
 |
Mettler-Toledo International
MTD
|
863 M | $ 1 384.16 | -0.62 % | $ 29.4 B |  Schweiz |
 |
ICON Public Limited Company
ICLR
|
791 M | $ 179.07 | -3.67 % | $ 14.8 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
888 M | $ 674.78 | -0.29 % | $ 55.6 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
3.32 B | $ 28.73 | -1.79 % | $ 20 B | Niderland |
 |
Agilent Technologies
A
|
1.21 B | $ 132.75 | -0.37 % | $ 40.4 B | USA |
 |
Biomerica
BMRA
|
-4.97 M | $ 2.39 | 0.21 % | $ 5.49 M | USA |